NCT00405652已完成3 期
Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients (MyLiver)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Changes in Gastrointestinal Symptom Severity and Health Related Quality of Life
研究概览
简要总结
Treatment with the immunosuppressive drug mycophenolate mofetil (MMF) may result in gastrointestinal (GI) complications in some patients. This study will assess if a switch from MMF to enteric-coated mycophenolate sodium (EC-MPS) results in improved GI and/or health-related quality of life in liver transplant recipients
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Received liver transplant at least 3 months prior to study enrollment.
- •Receiving immunosuppressive regimen that includes a calcineurin or mTOR inhibitor, and MMF at time of study enrolment. The patient must be stable on current immunosuppressive regimen. The MMF dose must be stable for at least 1 month prior to enrollment. Steroid use will be according to local practice.
- •Patients can only be enrolled into the study if it is expected that treatment will continue at the same dose until study end (6-8 weeks after enrollment).
- •Patients with a medical condition that necessitates MPA-treatment for probably the next 6- 8 weeks (time of study duration).
- •Patients with at least mild overall Gastrointestinal (G)I complications as assessed by the GI complications Case Report Form(CRF).
- •Eligible and willing to convert to Myfortic.
- •At lease 18 years of age.
- •Willing to provide written informed consent.
- •Able to meet all study requirements including completing the questionnaires and completing 2 study visits.
- •Patients receiving drugs that may cause GI symptoms such as bisphosphonates, minerals, vitamins, antibiotics or proton pump inhibitors (PPIs) have to be on a stable dose of these substances for at least 1 month prior to enrollment. Patients receiving these drugs can only be enrolled into the study, if it is expected that treatment will continue at the same dose until study end (6-8 weeks after enrollment).
- •Females capable of becoming pregnant must have a negative pregnancy test within 7 days prior to or at baseline. Pregnancy test has to be repeated every 4 weeks. Females are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility.
- •Exclusion criteria:
- •If applicable, GI symptoms assumed or know not to be caused by MPA therapy (e.g. oral bisphosphonates induced, infections diarrhea).
- •Acute rejection <1 week prior to study enrollment
- •Patients with Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and or/ bilirubin values >=3 x Upper limit normal (ULN) (values available from the last routine assessment within 3 months are acceptable).
- •Patients with serum creatinine values >=265 umol/L (values available from the last routine assessment within 3 month are acceptable).
- •Patients with hemoglobin values <7g/dL and/or an absolute platelet count of <50 x 10^9/L and /or an absolute leukocytes count of <2.0 x10^9/L (values available from the last routine assessment within 3 month are acceptable.)
- •Woman of child-bearing potential who is planning to become pregnant or is pregnant and/or lactating or who is unwilling to use effective means of contraception.
- •Presence of psychiatric illness (i.e., schizophrenia, major depression) that, in the opinion of the site investigator, could interfere with study requirements.
- •Undergoing acute medical intervention or hospitalization.
- •Presence of a medical condition not related to a GI event at the time of visit, which requires immediate medical intervention.
- •Any other medical condition that, in the opinion of the site investigator based on recall or chart review, interfere with completing the study, including but not limited to, visual problems or cognitive impairment.
- •Receiving any investigational drug or have received any investigational drug within 30 days prior to study enrollment.
- •Patients with hypersensitivity to mycophenolate sodium, mycophenolic acid, mycophenolic mofetil or other components of the formulation (e.g. lactose; see also SmPCs)
- •Other protocol-defined inclusion/exclusion criteria may apply.
排除标准
- 未提供
研究组 & 干预措施
Enteric-coated Mycophenolate sodium
Experimental
Enteric-coated Mycophenolate sodium (EC-MPS), administered orally twice a day to achieve a dose equimolar to the dose of Mycophenolate mofetil (MMF) the patient was taking at the time of study entry up to a maximum dose of 1440 mg.
干预措施: Enteric-coated Mycophenolate sodium (EC-MPS) (Drug)
结局指标
主要结局
Changes in Gastrointestinal Symptom Severity and Health Related Quality of Life
时间窗: Baseline, End of Study (6-8 weeks)
Change in Gastrointestinal symptom rating scale (GSRS) total score from baseline visit to follow-up visit 6-8 weeks after treatment. The GSRS has 5 subscales (reflux, diarrhea, constipation, abdominal pain, and indigestion) producing a mean subscale score ranging from 1 (no discomfort) to 7 (very severe discomfort). The GSRS total score was computed by the mean of the subscale scores.
次要结局
- The Number of Participants With Subclinical Rejection as Evaluated by a Change in Liver Enzymes(12-20 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney TransplantsPancreas TransplantationKidney TransplantationNCT00267150Novartis Pharmaceuticals31
已完成
3 期
Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With MycophenolateAutoimmune DiseaseNCT00351377Novartis Pharmaceuticals111
已完成
4 期
Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)Renal TransplantationGastrointestinal ProblemsNCT00149968Novartis196
已完成
4 期
Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) IntoleranceRenal TransplantationNCT00400400Novartis Pharmaceuticals400
已完成
4 期
Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) TherapyKidney TransplantationLiver TransplantationNCT00149942Novartis23